Empagliflozin, dapagliflozin, canagliflozin — the diabetes drugs that quietly do more than metformin. The honest accounting of mechanism, cardiovascular protection, kidney benefits, and how to think about them within a coaching framework where lifestyle remains the primary intervention.
If Post 1 made the case that metformin’s reputation has been mythologized in places, this post is going to make a different argument: the SGLT2 inhibitor class — Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin) — has been underrated in the patient conversation. Most patients on these drugs don’t fully understand what the medication is actually doing. And the cardiovascular outcomes and kidney protection data that have emerged over the last decade place this class in a different evidence tier from the older glucose-lowering drugs.
But before walking through the evidence, the foundational framework needs to be explicit. Proper nutrition and exercise will always be the primary intervention in my coaching practice. The dietary changes that clear ectopic fat from the liver and pancreas. The resistance training that restores insulin sensitivity at the cellular level. The sleep, stress management, and metabolic flexibility work that addresses the underlying drivers of the disease. Pharmaceuticals — even the best ones in this series — are bridges to better health. They support the work. They buy time during the transition. They don’t replace lifestyle change. And as this post will show, even mechanistically, the SGLT2 inhibitor class doesn’t deliver the weight loss that its calorie-deficit math would predict, because the body compensates with increased appetite. The drugs work better as adjuncts to lifestyle than they do as substitutes for it.
This framework just received its strongest current endorsement. The June 2026 American Heart Association / American College of Cardiology / American Diabetes Association / American Society of Nephrology joint guideline on Cardiovascular-Kidney-Metabolic (CKM) Syndrome — the first-ever comprehensive guideline integrating these conditions — explicitly positions “healthy lifestyle behaviors” as foundational, with SGLT2 inhibitors and GLP-1-based therapies recommended as add-on therapy alongside lifestyle modification, not as replacements for it. The guideline identifies excessive or dysfunctional adiposity as the underlying driver of the entire syndrome cluster. That framing aligns directly with the model the diabetes series has been building.
One more note before getting into the data. After Post 1 was published, a reader in medical practice brought forward a thoughtful, citation-heavy contribution that resulted in a number of precision refinements — UKPDS 91 added, beta cell framing softened, exercise interaction nuance acknowledged. That exchange set the standard for the rest of this series. The posts going forward are written with that same standard from the start. Where the evidence is more nuanced than initial framing might suggest, I’m naming it explicitly. Where findings are drug-specific within a class, I’m distinguishing them from class-wide effects. Where my coaching interpretation differs from standard guideline positions, I’m calling that out.
Working as always to provide the most pertinent information for you to get the conversation started with your doctor. If I were to include all data the post would be too long and this is where people contributing matters and questions being asked matters as I always respond. My belief and expectation of my doctors (and I believe should be of all doctors) is that the conversation should always include your doctor having very direct conversations with you about hiring someone for nutrition because chances are they don’t truly know nutrition and you don’t either, following a exercise program with strength training at the core (allocating funds perhaps for 6 months to a year to learn), and supplementing.
This is Part 1 of the SGLT2 conversation. Part 2 will cover the liver fat data and the critically important safety conversation for patients combining these drugs with low-carbohydrate or ketogenic dietary approaches. I’m going to use empagliflozin (Jardiance) as the lead example throughout because it has the most extensive cardiovascular and kidney outcomes data, but the mechanism and most of the class effects apply across the SGLT2 inhibitor family. Where findings are specifically empagliflozin-driven and don’t fully extrapolate to the rest of the class, I’ll say so.
How SGLT2 inhibitors actually work
This is the mechanism that almost nobody explains to patients, and once you understand it, the entire drug class makes more sense.
In healthy adults, the kidneys filter approximately 160-180 grams of glucose per day from the bloodstream, and nearly all of it gets reabsorbed back into circulation through transport proteins in the proximal tubule of the nephron. About 80-90 percent of that glucose reabsorption happens through a single transporter called SGLT2 (sodium-glucose cotransporter 2). The remaining 10-20 percent is reabsorbed through SGLT1, a different transporter located further down the proximal tubule.
SGLT2 inhibitors block the SGLT2 transporter. This forces the kidneys to dump glucose into the urine instead of reabsorbing it back into the bloodstream. At therapeutic doses, the amount of glucose lost in urine each day is substantial:
- Empagliflozin 10 mg: approximately 64 grams of glucose excreted per day in urine
- Empagliflozin 25 mg: approximately 78 grams per day
- Across the class generally: 60-90 grams per day
Glucose contains roughly 4 calories per gram. So the urinary glucose excretion translates to a sustained caloric deficit of roughly 240-320 calories per day, imposed pharmacologically, that the patient experiences whether they consciously change their diet or not.
But here’s where the coaching framework matters, because the math doesn’t translate cleanly into outcomes. Based on the imposed caloric deficit alone, a patient on empagliflozin should lose approximately 7 kg of body weight over 24 weeks. That’s what energy balance arithmetic predicts. The actual observed weight loss in clinical trials is 2-3 kg over the same period — roughly one-third of what the calorie math predicts.
The gap is explained by compensatory hyperphagia. The body recognizes the caloric loss through urine and responds by increasing appetite and food intake to make up most of the deficit. Patients on SGLT2 inhibitors eat more, often unconsciously, in response to the metabolic stress signal the drug creates. The pharmacologically-imposed deficit gets partially erased by the biological response to it.
This is not a flaw in the drug. It’s a feature of human physiology — the same compensatory response that makes intentional caloric restriction so hard to sustain long-term. And it’s the cleanest mechanistic evidence I can point to for why drugs alone don’t deliver what the marketing implies they should. A medication that creates a 300-calorie daily deficit on paper produces less than a third of the weight loss that deficit should yield, because the body fights back through appetite. Patients who pair the medication with intentional dietary work and resistance training — addressing both the imposed deficit AND the compensatory appetite response — see substantially better outcomes than patients who rely on the drug alone.
That’s the framework for thinking about every SGLT2 benefit in this post. The drug does meaningful things. The body responds in ways that partially offset those benefits. The lifestyle interventions that address the underlying ectopic fat accumulation and metabolic dysregulation are what convert the drug’s effect into durable improvement.
The downstream metabolic effects — modest weight loss (typically 2-3 kg over 24 weeks), blood pressure reduction (3-5 mmHg systolic), HbA1c reduction of about 1 percent — all flow from the mechanism plus secondary metabolic adaptations the body makes in response to the imposed glucose deficit.
The mechanism is also insulin-independent. This is clinically important: SGLT2 inhibitors don’t force the pancreas to produce more insulin, which means they don’t drive beta cell exhaustion the way sulfonylureas do, and they don’t cause hypoglycemia on their own (only in combination with insulin or sulfonylureas). For patients further along in the disease, where beta cell function is already declining, this matters.
The cardiovascular outcomes data
This is where the SGLT2 inhibitor class moved into a different evidence tier from metformin, and it’s worth walking through carefully because the standard prescribing conversation often doesn’t capture the magnitude of what these trials showed — and because the distinction between empagliflozin-specific findings and class-wide effects matters more here than the average patient conversation acknowledges.
EMPA-REG OUTCOME was the landmark cardiovascular outcomes trial for empagliflozin, published in the New England Journal of Medicine in 2015. It randomized 7,020 patients with type 2 diabetes and established cardiovascular disease to empagliflozin (10 mg or 25 mg) or placebo, with a median follow-up of 3.1 years. The results in this specific population:
- 14% reduction in the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) — HR 0.86, 95% CI 0.74-0.99, p=0.04
- 38% reduction in cardiovascular mortality alone — HR 0.62, 95% CI 0.49-0.77, p<0.001
- 35% reduction in hospitalization for heart failure — HR 0.65, 95% CI 0.50-0.85, p=0.002
- 32% reduction in all-cause mortality — HR 0.68, 95% CI 0.57-0.82
These are substantial effect sizes, especially the cardiovascular mortality reduction. But here’s the precision point that matters: these specific effect sizes are empagliflozin-specific findings in patients with established cardiovascular disease. They do not all extrapolate cleanly to the rest of the SGLT2 inhibitor class or to lower-risk populations.
The 2025 European Society of Cardiology Heart Failure Association Scientific Statement on SGLT2 inhibitors notes explicitly that across the cardiovascular outcome trials of empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, “the results of the trials differed with respect of major CV events and CV deaths, with significant reduction in CV death only in EMPA-REG OUTCOME trial.” That’s an important nuance. The reduction in heart failure hospitalization, by contrast, was consistent across all trials with no significant heterogeneity — that finding does represent a true class-wide effect.
When you pool the SGLT2 inhibitor class across multiple trials, the effect sizes look more modest than EMPA-REG OUTCOME alone would suggest. A 2026 meta-analysis of 15 RCTs covering 28,484 heart failure patients found SGLT2 inhibitor therapy was associated with a 14% reduction in all-cause mortality (HR 0.86, 95% CI 0.79-0.92, p<0.001) and a 26% reduction in heart failure hospitalization (HR 0.74, 95% CI 0.68-0.81, p<0.001). Another multi-treatment meta-analysis of 6 cardiovascular outcome trials covering 46,969 patients found pooled effects of HR 0.85 for all-cause mortality (NNT 58), HR 0.91 for MACE (NNT 81), and HR 0.70 for heart failure hospitalization (NNT 32).
So the honest framing has two layers. Empagliflozin in patients with established cardiovascular disease shows the strongest cardiovascular mortality data in the class — that EMPA-REG OUTCOME 38% reduction in CV death is real, well-documented, and forms the basis for empagliflozin’s FDA indication for reducing cardiovascular mortality in this population. The SGLT2 class more broadly demonstrates consistent reductions in heart failure hospitalization and kidney outcomes, with more modest pooled effects on all-cause mortality (roughly 14-15% across the class). Both pictures are true. Which one applies to your specific situation depends on which drug you’re on, what your underlying risk profile looks like, and which population the trial data was derived from.
The mechanism of these cardiovascular benefits is genuinely not fully understood and appears to extend beyond glucose lowering. Multiple analyses suggest the heart failure benefits in particular are largely independent of glycemic control — they appear with similar effect sizes in non-diabetic patients. The current best hypotheses involve effects on cardiac energy metabolism, reduced cardiac preload through natriuresis, improvements in vascular function, and reductions in inflammation and oxidative stress.
The heart failure data — for patients with or without diabetes
Following EMPA-REG OUTCOME, two larger trials examined empagliflozin specifically in heart failure populations, including patients without diabetes.
EMPEROR-Reduced (2020) randomized 3,730 patients with heart failure with reduced ejection fraction (HFrEF) to empagliflozin 10 mg or placebo, regardless of diabetes status. Empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 25 percent (HR 0.75, 95% CI 0.65-0.86). The benefit was consistent in patients with and without diabetes.
EMPEROR-Preserved (2021) extended the trial design to patients with heart failure with preserved ejection fraction (HFpEF) — a condition that had essentially no effective pharmacological treatments before this trial. The trial randomized 5,988 patients to empagliflozin 10 mg or placebo, with a median follow-up of 26 months. Empagliflozin reduced the primary composite outcome (cardiovascular death or heart failure hospitalization) by 21 percent (HR 0.79, 95% CI 0.69-0.90, p<0.001). The benefit, again, was independent of diabetes status. This reduction was primarily driven by lower heart failure hospitalization rates rather than reduced cardiovascular death.
The FDA expanded the indication for empagliflozin in 2021 to include heart failure with reduced ejection fraction, and in 2022 to include heart failure regardless of ejection fraction — both indications applying to patients without diabetes. This is a glucose-lowering drug now formally indicated for cardiac conditions in patients who don’t have the metabolic disease the drug was originally developed for.
An honest counterweight: not every SGLT2 trial has been positive. The EMPACT-MI trial (2024), which tested empagliflozin in patients with acute myocardial infarction at increased risk of heart failure, did NOT meet its primary composite endpoint of heart failure hospitalization or all-cause death. A parallel trial of dapagliflozin in post-MI patients (DAPA-MI, 2024) also did not show definitive reduction in post-infarction mortality or heart failure hospitalization on its primary endpoint, though secondary cardiometabolic outcomes were favorable. A 2025 secondary analysis of EMPACT-MI did show kidney function preservation and confirmed safety of initiation in post-MI patients, but the headline result for primary cardiovascular outcomes was negative. These trials matter for the honest accounting: empagliflozin and the SGLT2 class are not universally effective across every cardiovascular population. The strong benefits seen in EMPA-REG OUTCOME, EMPEROR-Reduced, and EMPEROR-Preserved did not extend to the post-MI prevention setting in the way investigators had hoped. The drug class has limits, and the literature is honest about them when read fully.
The kidney protection data
EMPA-KIDNEY (NEJM, January 2023) was the broadest kidney outcomes trial conducted on this drug class. It randomized 6,609 patients with chronic kidney disease — most of them with significantly reduced kidney function (eGFR 20-45 mL/min/1.73m²) — to empagliflozin 10 mg or placebo. Crucially, 54 percent of enrolled patients did not have diabetes.
The primary outcome was a composite of kidney disease progression (end-stage kidney disease, sustained eGFR decline ≥40%, or renal death) or cardiovascular death. Results at a median 2-year follow-up:
- 28% reduction in the primary composite outcome — HR 0.72, 95% CI 0.64-0.82, p<0.001
- 29% reduction in kidney disease progression specifically — HR 0.71, 95% CI 0.62-0.81
- 50% reduction in the rate of chronic eGFR decline
The benefit was consistent across patients with and without diabetes, across a wide range of baseline kidney function, and across different underlying causes of kidney disease. The long-term follow-up published in NEJM in 2024 confirmed that benefits persisted after the trial period.
The clinical impact has been significant enough that the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease now recommends SGLT2 inhibitor therapy as a 1A recommendation (the highest evidence tier) for patients with type 2 diabetes and CKD with an eGFR ≥20 mL/min/1.73m². For patients without diabetes but with proteinuric CKD, the guidelines also recommend SGLT2 inhibitor therapy. This is the strongest possible guideline endorsement and reflects an evidence base substantially stronger than what older glucose-lowering drugs have demonstrated for kidney protection.
For nephrology, this is the largest evidence-based advance in slowing chronic kidney disease progression in decades — coming from a drug originally developed to lower blood glucose. The FDA approved empagliflozin for chronic kidney disease in 2023, again with the indication applying regardless of diabetes status.
The framework — SGLT2 inhibitors within a coaching protocol
The foundational principle of my coaching practice: proper nutrition and exercise are the primary intervention. Pharmaceuticals are bridges to better health, not replacements for the work that actually reverses metabolic disease. That framework applies to SGLT2 inhibitors as much as to any other drug class — though with important nuance based on individual clinical context.
The dietary changes that clear ectopic fat from the liver and pancreas, the resistance training that restores insulin sensitivity at the cellular level, the sleep and stress management that address the underlying drivers of metabolic disease — these are the disease-modifying interventions. SGLT2 inhibitors support the work but don’t replace it. And as I noted in the mechanism section, even the drug’s calorie-deficit math gets partially erased by the body’s compensatory appetite response — meaning the patient who combines the medication with intentional dietary work and resistance training gets substantially better outcomes than the patient who relies on the drug alone.
Within that foundational framework, SGLT2 inhibitors fit differently for different patient populations:
For patients with established cardiovascular or kidney disease, the SGLT2 inhibitor evidence base is strong enough that I would not approach these drugs as short-term bridges to be tapered quickly. The cardiovascular and renal protection is mechanistically distinct from glucose management, and the benefit appears to persist as long as treatment continues. For these patients, the drug may legitimately be a long-term part of the treatment plan even after lifestyle changes have addressed the underlying metabolic disease. The June 2026 CKM Syndrome Guideline reflects this position — SGLT2 inhibitors as guideline-directed medical therapy alongside, not instead of, lifestyle modification.
For patients without established cardiovascular or kidney disease, the framework is more similar to metformin — SGLT2 inhibitors as glucose support and metabolic adjuncts while lifestyle intervention addresses the underlying ectopic fat, with the possibility of tapering as the disease state resolves. The decision should be coordinated with the prescribing physician based on individual risk factors. The patients I work with who do the lifestyle work successfully often find their medication needs decrease as their underlying disease improves.
To be clear about my framing: the “drugs as adjuncts to lifestyle” framework I use as a coach is well-supported by the new 2026 CKM Syndrome Guideline, which positions healthy lifestyle behaviors as foundational with cardioprotective antihyperglycemic agents (SGLT2 inhibitors and GLP-1-based therapies) as add-on therapy. That alignment between coaching philosophy and current authoritative guideline is new — and worth naming. The major endocrinology societies still also position SGLT2 inhibitors as durable first-line therapy for many patient populations with established cardiovascular or kidney disease, particularly where the outcomes data supports sustained use.
The pattern across every patient population I work with: the drug is most effective as part of a comprehensive treatment plan that includes the dietary, training, sleep, and stress management work. The patients who treat the medication as the treatment plan, without doing the lifestyle work, see less benefit than the patients who treat the medication as one component of a broader effort to reverse the underlying disease.
Where this leaves us — Part 1
SGLT2 inhibitors are quietly one of the most consequential drug classes in modern internal medicine. The cardiovascular outcomes data places them in a different evidence tier from older glucose-lowering drugs — with the caveat that the strongest mortality reductions are empagliflozin-specific in patients with established cardiovascular disease, and class-wide effects are more modest when pooled across all SGLT2 inhibitors and all populations. The kidney protection data extends their utility beyond diabetes entirely, and the KDIGO 2024 guidelines now position SGLT2 inhibitors as 1A first-line therapy for T2D with CKD. The heart failure data has changed practice patterns in cardiology, with the heart failure hospitalization reduction being one of the most consistent class-wide findings.
But the most important takeaway from this post, from a coaching perspective, is the framework: proper nutrition and exercise are the primary intervention. SGLT2 inhibitors are bridges to better health, not replacements for the work that actually reverses metabolic disease. The June 2026 CKM Syndrome Guideline reinforces exactly this position — lifestyle as foundational, medications as add-on. The compensatory hyperphagia data shows that even the drug’s calorie-deficit math gets partially erased by the body’s appetite response when lifestyle isn’t doing its part. The patients who get the most benefit from this drug class are the ones who pair it with intentional dietary work, resistance training, sleep, and stress management — using the medication to support a comprehensive treatment plan rather than to substitute for one.
If you’re on Jardiance, Farxiga, or Invokana, the drug is dumping 60-90 grams of glucose into your urine every day, imposing a 240-320 calorie deficit, lowering your blood pressure, protecting your kidneys, and reducing your cardiovascular event risk in ways that are partially distinct from the glucose lowering itself. That’s not nothing. But the drug alone won’t deliver what the lifestyle work compounded with the drug will.
What’s coming in Part 2
Part 2 of this SGLT2 conversation covers two topics that deserve their own focused treatment:
The liver fat data. The SGLT2 inhibitor class shows interesting effects on hepatic steatosis (fatty liver), with emerging evidence in both diabetic and non-diabetic populations. The data is genuinely promising but more nuanced than headline trial results suggest, and recent meta-analyses have introduced important caution.
The safety conversation that matters most for low-carb patients. Euglycemic diabetic ketoacidosis — DKA without the elevated glucose readings that normally signal it — is a real and underappreciated risk on SGLT2 inhibitors, and the risk is elevated significantly by ketogenic or very-low-carbohydrate dietary approaches. This is the single most important medication-coaching intersection in this entire series for the audience I work with, and it deserves its own focused treatment rather than being buried within a longer post about cardiovascular outcomes.
Part 2 publishes next. If you’re on an SGLT2 inhibitor AND following a low-carb or ketogenic dietary approach, that post is essential reading.
A note on what this is and isn’t
This series is educational content built from peer-reviewed research, clinical trial data, and my work as a nutrition and fitness coach. It is not medical advice. I am not a physician. The information here is designed to give you the framework and the questions to bring to your own medical team — not to replace that team.
Do not stop or adjust any SGLT2 inhibitor based on what you’ve read here. These drugs are often prescribed for serious cardiovascular, renal, or hepatic indications, and discontinuation should be coordinated with your prescribing physician.
Find a physician who works with you on the framework. If you’ve been on an SGLT2 inhibitor for years without anyone discussing the safety considerations, the lifestyle interventions that compound the drug’s benefits, or the long-term cardiovascular and renal monitoring that should accompany this drug class — those conversations are worth having.
Individual results vary. Trial data describes populations. You are an individual with your own medical history, comorbidities, and clinical context. The general framework in this post will not be the right framework for every reader. Use your judgment. Talk to your team. Ask the questions.
The goal of this work has always been informed patients, not stopped medications. For SGLT2 inhibitors specifically, the more accurate framing is informed patients who understand what the drug is actually accomplishing AND what the lifestyle work needs to look like alongside the medication — because for many patients, this drug class is doing more than they realize, and continuing it appropriately while doing the dietary and training work that actually reverses the underlying disease is often the right call.
The medication is the bridge. Nutrition and exercise are the destination. That framework drives everything in this practice, and the June 2026 CKM Syndrome Guideline now formally endorses it as the standard for cardiovascular-kidney-metabolic disease management.
You have the framework. The work is yours.
One BadAss BITCH 